Program
acoramidis
Also written as “Acoramidis”, “Acoramidis (AG10)” and “AG10”.
Its studies are mostly in Amyloid Neuropathies, Familial · Amyloidosis, Hereditary, Transthyretin-Related · Amyloidosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBio | 114 open or running | phase 4since Jul 6, 2026 | Sep 18, 2017 | Apr 15, 2028phase 3 · NCT04988386 |
| AstraZeneca | 31 open or running | phase 4since Dec 15, 2025 | Nov 6, 2020 | Mar 31, 2028phase 4 · NCT07306949 |
| Bayer | 11 open or running | phase 4since Dec 11, 2025 | Dec 11, 2025 | Sep 17, 2027phase 4 · NCT07298044 |
Also a collaborator on its studies: celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 18, 2017.
- May 11, 2018Phase 2 study in Amyloid Neuropathies, FamilialBridgeBio · NCT03536767 · 47 enrolled · United States
- Feb 27, 2019Phase 3 study in AmyloidosisBridgeBio · NCT03860935 · 632 enrolled · United States, Australia, Belgium and more
- May 22, 2020Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04418024 · United States
- Nov 6, 2020AstraZeneca's first study: phase 3 study in Symptomatic Transthyretin Amyloid CardiomyopathyNew to AstraZenecaAstraZeneca · NCT04622046 · 25 enrolled · Japan
- Feb 19, 2021Phase 1 study in AmyloidosisBridgeBio · NCT04769479 · 14 enrolled · United Kingdom
- Apr 29, 2021Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04882735
- Jul 1, 2021Phase 1 study in HealthyAstraZeneca · NCT04958135 · 18 enrolled · United States
- Jul 13, 2021Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04988386 · 389 enrolled · United States, Australia, Belgium and more
- Aug 5, 2024Phase 3 study in AmyloidosisBridgeBio · NCT06563895 · 587 planned · United States, Argentina, Australia and more
- Aug 7, 2025Phase 3 study in Amyloidosis, FamilialBridgeBio · NCT07116473 · 250 planned
- Dec 11, 2025Bayer's first study: phase 4 study in Transthyretin Amyloid CardiomyopathyNew to BayerBayer · NCT07298044 · 50 planned · Austria, Belgium, Germany and more
- Dec 15, 2025Phase 4 study in Transthyretin-type Cardiac AmyloidosisAstraZeneca · NCT07306949 · 200 planned · Japan
- Jul 6, 2026Phase 4 study in AmyloidosisBridgeBio · NCT07695701 · 150 planned · United States
- Oct 14, 2026Phase 2 study terminatedStudy stoppedNCT03536767 · “Study ended by the sponsor due to meeting Study Objectives”
Ahead
- Sep 17, 2027Primary completion: phase 4 study in Transthyretin Amyloid CardiomyopathyBayer · NCT07298044
- Mar 31, 2028Primary completion: phase 4 study in Transthyretin-type Cardiac AmyloidosisAstraZeneca · NCT07306949
- Apr 15, 2028Primary completion: phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04988386
- Aug 2030Primary completion: phase 4 study in AmyloidosisBridgeBio · NCT07695701
TargetBeta
“Transthyretin stabiliser; Transthyretin stabiliser”ChEMBL 37, by rule
Other programs on TTR
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07695701Amyloidosis · United States | 4 | Recruiting | BridgeBio | Aug 2030 | 150 |
| NCT07306949Transthyretin-type Cardiac Amyloidosis · Japan | 4 | Recruiting | AstraZeneca | Mar 31, 2028 | 200 |
| NCT07298044Transthyretin Amyloid Cardiomyopathy · Austria, Belgium, Germany and more | 4 | Recruiting | Bayer | Sep 17, 2027 | 50 |
| NCT07116473Amyloidosis, Familial | 3 | Not yet recruiting | BridgeBio | Nov 2037 | 250 |
| NCT06563895Amyloidosis · United States, Argentina, Australia and more | 3 | Recruiting | BridgeBio | Oct 2031 | 587 |
| NCT04988386Amyloid Neuropathies, Familial · United States, Australia, Belgium and more | 3 | Active, not recruiting | BridgeBio | Apr 15, 2028 | 389 |
| NCT04958135Healthy · United States | 1 | Completed | AstraZeneca | Aug 4, 2021 | 18 |
| NCT04882735Amyloid Neuropathies, Familial | 3 | Withdrawn | BridgeBio | Sep 2026 | 0 |
| NCT04769479Amyloidosis · United Kingdom | 1 | Completed | BridgeBio | Aug 4, 2021 | 14 |
| NCT04622046Symptomatic Transthyretin Amyloid Cardiomyopathy · Japan | 3 | Completed | AstraZeneca | Nov 8, 2023 | 25 |
| NCT04418024Amyloid Neuropathies, Familial · United States | 3 | Withdrawn | BridgeBio | Mar 31, 2024 | 0 |
| NCT03860935Amyloidosis · United States, Australia, Belgium and more | 3 | Completed | BridgeBio | May 11, 2023 | 632 |
| NCT03536767Amyloid Neuropathies, Familial · United States | 2 | Terminated | BridgeBio | Sep 15, 2025 | 47 |
| NCT03458130Familial ATTR-CM (ATTRm-CM, or FAC) · United States | 2 | Completed | BridgeBio | Oct 5, 2018 | 49 |
| NCT03294707Amyloid Neuropathies, Familial · United States | 1 | Completed | BridgeBio | Feb 5, 2018 | 56 |
How it is read
Names in the registry
- “Acoramidis”, 6 entries
- “Acoramidis (AG10)”, 2 entries
- “AG10”, 2 entries
- “acoramidis”, 2 entries
- “Acoramidis (AG10) oral tablet”, 1 entry
Conditions, from the studies’ own filings
- Amyloid Neuropathies, Familial, 5 studies
- Amyloidosis, Hereditary, Transthyretin-Related, 4 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.